重组人血管内皮抑素联合化疗治疗晚期胃肠道癌临床观察
高绍荣;夏海平;徐红燕;殷军蕾;郭辉
【期刊名称】《中国实用医刊》 【年(卷),期】2013(040)004
【摘要】Objective To observe the clinical effect and drug safety of endostar combined with chemotherapy in treatment of advanced gastrointestinal
cancer.Methods
Sixteen
cases
of
advanced
gastrointestinal cancer were confirmed for adenocarcinoma by pathological or cytologic examination.Endostar 15 mg was given by intravenous
drip,once
a
day
for
14
days.Chemotherapy
regimen:FOLFIRI:Irinotecan(180 mg/m2) iv infusion for 90 min; LV(CF) 200 mg/m2,iv,d1 ; 5-Fu 400 mg/m2,iv,d1 ; 5-Fu 2400 mg/m2,Continued vein pump into for 46 h.FOLFOX4:L-OHP 135 mg/m2,iv for 2 h,d1 ; CF 200 mg/m2,iv,d1 ; 5-FU 400 mg/m2,d1,continued intravenous drip into with 2400 mg/m2 for 46 h after intravenous push.XELOX:Capecitabine 1500 mg/m2,twice a day,d1-d14; L-OHP 135 mg/m2,iv infusion for 2 h,d1.The improved scheme is changing 5-Fu of above two schemes into Tegafur 1.0 g,iv,d1-5.Ondansetron 8 mg was intravenously injected before chemotherapy to prevent vomiting.After chemotherapy,do the strengthening the body resistance,attenuation,symptomatic and supportive treatment,21 d each cycle,continuous for 4-6 cycles.Do effect assessment each 2 cycle.Results Among the 16 cases,RR(CR + PR) was
重组人血管内皮抑素联合化疗治疗晚期胃肠道癌临床观察
